Brokers Set Expectations for ESPR Q1 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings of ($0.16) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q2 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.01) EPS.

ESPR has been the topic of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Trading Down 3.6 %

Shares of NASDAQ:ESPR opened at $1.59 on Thursday. The company has a market capitalization of $313.29 million, a PE ratio of -2.48 and a beta of 1.01. Esperion Therapeutics has a twelve month low of $1.57 and a twelve month high of $3.94. The firm has a 50 day simple moving average of $1.97 and a 200-day simple moving average of $2.08.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of the company. Wasatch Advisors LP increased its stake in Esperion Therapeutics by 4.9% in the 4th quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock valued at $53,861,000 after buying an additional 1,136,245 shares during the period. Geode Capital Management LLC increased its stake in Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares during the period. State Street Corp increased its stake in Esperion Therapeutics by 2.7% in the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after buying an additional 99,802 shares during the period. Two Sigma Advisers LP grew its stake in shares of Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after purchasing an additional 16,100 shares during the period. Finally, Nuveen Asset Management LLC increased its holdings in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.